

# ICER Mixes Up Priorities in Asthma Drug Review

The Institute for Clinical and Economic Review's analysis paints an inaccurate picture of the benefits created by a new medication for severe asthma.

## ••• Ignores the value of expanding treatment options

Patients are more likely to find an effective treatment when more options are available. Controlling asthma and its symptoms reduces dangerous exacerbations, related physician appointments and visits to the ER.

## ••• Overlooks the value of treatment for communities of color

ICER overlooks the new medication's value to communities of color, even though:

- Black Americans are five times more likely to visit the emergency room due to asthma
- Puerto Ricans have a nearly three-fold higher rate of asthma-related deaths
- Native Americans are nearly twice as likely to experience asthma symptoms every day



## ••• Negates the value of a novel mechanism of action

The new medication's novel mechanism of action is an important addition to the asthma community's treatment options.

## ••• Inflates long-term costs

The cost of asthma medication will stretch across a lifetime. But the price of a new treatment will decline over time as prices drop and competition expands. ICER fails to include this consideration in its calculations.

ICER's priorities differ from severe asthma patients', and the economists' approach could make it harder for patients to access the treatment they need.



Institute for  
Patient Access